Trial of THEO-260 in Ovarian Cancer Patients

Summary

A research study evaluating a new oncolytic virus, THEO-260, in patients with advanced ovarian cancer. The trial will investigate different doses of THEO-260 administered intravenously to identify a dose that is safe, well tolerated, and exhibits preliminary evidence of anti tumour activity.

Timeline

Start

2024-09-24

Primary completion

2028-06

Completion

2028-06

Drugs

Indications